🇺🇸 FDA
Patent

US 8809370

AMPK-activating heterocyclic compounds and methods for using the same

granted A61PA61P1/04A61P1/14

Quick answer

US patent 8809370 (AMPK-activating heterocyclic compounds and methods for using the same) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P1/04, A61P1/14, A61P1/16, A61P1/18